A detailed history of Morgan Stanley transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Morgan Stanley holds 692,541 shares of SMMT stock, worth $5.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
692,541
Previous 704,272 1.67%
Holding current value
$5.22 Million
Previous $1.84 Million 55.98%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$2.55 - $5.07 $29,914 - $59,476
-11,731 Reduced 1.67%
692,541 $2.87 Million
Q4 2023

Feb 13, 2024

BUY
$1.67 - $2.83 $248,723 - $421,488
148,936 Added 26.82%
704,272 $1.84 Million
Q3 2023

Nov 15, 2023

SELL
$1.54 - $2.42 $56,441 - $88,693
-36,650 Reduced 6.19%
555,336 $1.04 Million
Q2 2023

Aug 14, 2023

SELL
$1.32 - $2.81 $234,676 - $499,575
-177,785 Reduced 23.1%
591,986 $1.49 Million
Q1 2023

May 15, 2023

BUY
$1.38 - $5.41 $760,150 - $2.98 Million
550,834 Added 251.59%
769,771 $1.35 Million
Q4 2022

Feb 14, 2023

SELL
$0.68 - $5.31 $90,032 - $703,044
-132,400 Reduced 37.68%
218,937 $930,000
Q3 2022

Nov 14, 2022

BUY
$0.89 - $1.63 $126,508 - $231,694
142,144 Added 67.95%
351,337 $418,000
Q2 2022

Oct 27, 2022

SELL
$0.92 - $2.38 $108,915 - $281,758
-118,386 Reduced 36.14%
209,193 $209,000
Q2 2022

Aug 15, 2022

SELL
$0.92 - $2.38 $108,915 - $281,758
-118,386 Reduced 36.14%
209,193 $209,000
Q1 2022

Oct 27, 2022

BUY
$2.0 - $3.45 $236,772 - $408,431
118,386 Added 56.59%
327,579 $803,000
Q1 2022

May 13, 2022

SELL
$2.0 - $3.45 $61,210 - $105,587
-30,605 Reduced 8.54%
327,579 $803,000
Q4 2021

Feb 14, 2022

BUY
$2.45 - $5.64 $196,583 - $452,542
80,238 Added 28.87%
358,184 $963,000
Q3 2021

Nov 15, 2021

BUY
$4.83 - $8.27 $1.34 Million - $2.3 Million
277,946 New
277,946 $1.39 Million

Others Institutions Holding SMMT

About Summit Therapeutics Inc.


  • Ticker SMMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 201,215,008
  • Market Cap $1.52B
  • Description
  • Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...
More about SMMT
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.